Hellenic National Center for Research, Prevention and Treatment of Diabetes Mellitus and its Complications (HNDC), Athens, Greece.
Eur J Endocrinol. 2010 Jan;162(1):121-6. doi: 10.1530/EJE-09-0622. Epub 2009 Oct 16.
Although insulin resistance is a common finding in hyperthyroidism, the implicated mechanisms are obscure. The aim of this study was to investigate whether interleukin 6 (IL6) and tumour necrosis factor alpha (TNFalpha) are related to the development of insulin resistance in hyperthyroidism of nonautoimmune origin.
A meal was given to ten hyperthyroid (HR) and ten euthyroid (EU) women. Plasma samples were taken for 360 min from the radial artery for measurements of glucose, insulin, and nonesterified fatty acids (NEFA). IL6 and TNFalpha were measured preprandially from the superficial epigastric vein and from the radial artery.
i) In HR versus EU: (a) arterial glucose was similar (AUC(0-360) 2087+/-57 vs 2010+/-43 mM x min), but insulin was increased (AUC(0-360) 17 267+/-2447 vs 10 331+/-666 microU/ml x min, P=0.01), (b) homeostasis model assessment (HOMA) was increased (2.3+/-0.4 vs 1+/-0.1 kg/m(2), P=0.007), (c) arterial NEFA were increased (AUC(0-360) 136+/-18 vs 89+/-7 mmol/lxmin, P=0.03), (d) arterial IL6 (2+/-0.3 vs 0.9+/-0.1 pg/ml, P=0.0009) and TNFalpha (4.2+/-0.8 vs 1.5+/-0.2 pg/ml, P=0.003) were increased, and (e) IL6 production from the subcutaneous adipose tissue (AT) was increased (18+/-6 vs 5+/-1 pg/min per 100 ml tissue, P=0.04). ii) (a) Subcutaneous venous IL6 was positively associated with HOMA (beta-coefficient=1.7+/-0.7, P=0.049) and (b) although TNFalpha was not produced by the subcutaneous AT, arterial TNFalpha was positively associated with NEFA (AUC(0-360); beta-coefficient=0.045+/-0.01, P=0.005).
In hyperthyroidism: i) glucose and lipid metabolism are resistant to insulin, ii) subcutaneous AT releases IL6, which could then act as an endocrine mediator of insulin resistance, iii) although there is no net secretion of TNFalpha by the subcutaneous AT, increased systemic TNFalpha levels may be related to the development of insulin resistance in lipolysis.
尽管胰岛素抵抗是甲状腺功能亢进症的常见表现,但涉及的机制尚不清楚。本研究的目的是探讨白细胞介素 6(IL6)和肿瘤坏死因子 alpha(TNFalpha)是否与非自身免疫性甲状腺功能亢进症中胰岛素抵抗的发生有关。
给 10 名甲状腺功能亢进(HR)和 10 名甲状腺功能正常(EU)的女性提供膳食。从桡动脉采集 360 分钟的血浆样本,以测量血糖、胰岛素和非酯化脂肪酸(NEFA)。餐前从腹壁浅静脉和桡动脉测量 IL6 和 TNFalpha。
i)在 HR 与 EU 之间:(a)动脉血糖相似(AUC(0-360)2087+/-57 与 2010+/-43 mM x min),但胰岛素升高(AUC(0-360)17 267+/-2447 与 10 331+/-666 microU/ml x min,P=0.01),(b)稳态模型评估(HOMA)升高(2.3+/-0.4 与 1+/-0.1 kg/m(2),P=0.007),(c)动脉 NEFA 升高(AUC(0-360)136+/-18 与 89+/-7 mmol/lxmin,P=0.03),(d)动脉 IL6(2+/-0.3 与 0.9+/-0.1 pg/ml,P=0.0009)和 TNFalpha(4.2+/-0.8 与 1.5+/-0.2 pg/ml,P=0.003)升高,(e)皮下脂肪组织(AT)的 IL6 产生增加(18+/-6 与 5+/-1 pg/min per 100 ml 组织,P=0.04)。ii)(a)皮下静脉 IL6 与 HOMA 呈正相关(β系数=1.7+/-0.7,P=0.049),(b)尽管 TNFalpha 不是由皮下 AT 产生的,但动脉 TNFalpha 与 NEFA 呈正相关(AUC(0-360);β系数=0.045+/-0.01,P=0.005)。
在甲状腺功能亢进症中:i)葡萄糖和脂质代谢对胰岛素有抵抗性,ii)皮下 AT 释放 IL6,这可能是胰岛素抵抗的内分泌介质,iii)尽管皮下 AT 没有 TNFalpha 的净分泌,但全身 TNFalpha 水平的增加可能与脂解过程中胰岛素抵抗的发生有关。